AIM — AIM ImmunoTech Share News
0.000.00%
Last trade - 00:00- $8.65m
- $6.99m
- $0.09m
Brief: Aim Immunotech announces commencement of Phase 2 study of Ampligen® for the treatment of pancreatic cancer
Brief: AIM Reiterates Intent To Proceed With Nominations And Proxy Solicitation
Brief: AIM Immunotech reports Q2 results
AIM ImmunoTech rises as drug shows promise in post-COVID condition
Brief: AIM Immunotech Reports Additional Patient Data From Single-Center Named Patient Program Evaluating Ampligen
AIM Immmunotech rejects activist investor's board nominations; shares down
Brief: AIM ImmunoTech Says Director Nominations From Jorgl Activist Group Are Invalid
Brief: AIM ImmunoTech Says Director Nominations From Jorgl Activist Group Are Invalid
Brief: Aim Immunotech Inc Secures New State-Of--Art Facility For Product Development And Testing
Brief: AIM ImmunoTech Bolsters Intellectual Property Portfolio For Ampligen With Issuance Of New Netherlands Utility Patent Covering Ampligen And Other AIM Developed dsRNA Products For Use In Covid-19 Treatment Or Prevention
Brief: AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program
Brief: AIM Immunotech Reports Q1 Loss From Operations Of $3.8 Mln
AIM up on data supporting use of Ampligen as combination therapy for cancer
Brief: AIM Provides Summary Of Ampligen Data Supporting Synergistic Potential With Checkpoint Blockade Therapies
U.S. RESEARCH ROUNDUP-Edwards Lifesciences, Intuitive Surgical, Thor Industries
Brief: AIM ImmunoTech Provides Progress on Advancement of Ampligen Clinical Program for Treatment of Pancreatic Cancer
AIM ImmunoTech rises after Ampligen shows promise in cancer trials
Brief: Aim Immunotech Announces Positive Data From Phase 2A Study Evaluating Ampligen
Brief: Aim Immunotech Announces Positive Data From Phase 1 Study Evaluating Ampligen